Last $112.24 USD
Change Today +0.53 / 0.48%
Volume 119.2K
TFX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 1:15 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Snapshot

Open
$111.71
Previous Close
$111.71
Day High
$112.37
Day Low
$111.04
52 Week High
11/28/14 - $119.99
52 Week Low
02/3/14 - $90.15
Market Cap
4.7B
Average Volume 10 Days
300.4K
EPS TTM
$4.32
Shares Outstanding
41.4M
EX-Date
11/12/14
P/E TM
26.0x
Dividend
$1.36
Dividend Yield
1.21%
Current Stock Chart for TELEFLEX INC (TFX)

Related News

No related news articles were found.

teleflex inc (TFX) Related Businessweek News

No Related Businessweek News Found

teleflex inc (TFX) Details

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company operates in three segments: Vascular, Anesthesia/Respiratory, and Surgical. It offers vascular access products that facilitate various critical care therapies, including the administration of intravenous medications and other therapies, the measurement of blood pressure, and taking of blood samples through a single puncture site; anesthesia products, such as airway management products under the LMA and Rusch brands, and pain management products under the Arrow brand; respiratory care products, such as oxygen therapy, aerosol therapy, spirometry, and ventilation management products under the Hudson RCI brand; and specialty products, including interventional access products, and products provided to specialty market customers. The company also provides surgical products, such as ligation and closure products used in surgical procedures; access ports for use in minimally invasive surgical procedures; fluid management products for use in chest drainage; and reusable hand-held instruments for general and specialty surgical procedures under the Deknatel, Pilling, Pleur-evac, Taut, and Weck brands. In addition, it offers cardiac care products comprising diagnostic catheters, including thermodilution and wedge pressure catheters; angiographic and therapeutic delivery catheters; sheaths for femoral and trans-radial aortic access, and intra-aortic balloons; and capital equipment, such as intra-aortic balloon pumps under the Arrow brand. Further, the company provides original equipment manufacturing and development services. Teleflex Incorporated offers its products to hospitals and healthcare providers in approximately 150 countries through its direct sales force and distributors. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

11,400 Employees
Last Reported Date: 02/24/14
Founded in 1943

teleflex inc (TFX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $826.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.5K
Executive Vice President and President of Ame...
Total Annual Compensation: $427.1K
Compensation as of Fiscal Year 2013.

teleflex inc (TFX) Key Developments

Teleflex to Focus on Advanced Interventional BTK (below the knee) Products at LINC 2015

Teleflex Incorporated will showcase its Arrow® brand GPSCath® interventional product platform at the Leipzig Interventional Course (LINC) to be held in Leipzig, Germany on January 27 - 30, 2015. During the event, the company will highlight the Arrow® GPSCath® Balloon Dilatation Catheter, which features the VisioValve technology. The GPSCath® Catheter is a specialty two-in-one device that is indicated for percutaneous transluminal angioplasty (PTA) in the peripheral vasculature, including iliac, femoral, popliteal, infrapopliteal and renal arteries.

Teleflex Incorporated Signs New Agreement with HealthTrust for PICC and Tip Location Devices

Teleflex Incorporated has signed a new agreement with HealthTrust covering peripherally inserted central catheter, or PICC, and tip location devices. Through this new agreement, HealthTrust members will have access to an extensive line of innovative ARROW PICC and tip location devices, including the ARROW PICC with Chlorag+ard Technology and the ARROW VPS Vascular Positioning System. The ARROW PICC with Chlorag+ard Technology has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. The ARROW VPS Vascular Positioning System uses a combination of advanced technologies. The VPS Stylet, when used with the VPS Console, provides real-time catheter tip location information by using the patient's physiological (cardiac electrical activity and blood flow) information. Employing a simple user interface and Blue Bullseye symbol to indicate proper catheter tip placement, the technology is designed to avoid clinical consequences such as thrombosis, arterial puncture and vessel wall damage. The ARROW VPS Vascular Positioning System is indicated for use as an alternate method to fluoroscopy or chest x-ray for central venous catheter tip placement confirmation in adult patients when a steady Blue Bullseye is obtained.

Teleflex Incorporated Reports Study Results of ARROWg+ard® Technology

Teleflex Incorporated announced that newly published research has reaffirmed the ability of catheters protected with ARROWg+ard® Technology to reduce both bloodstream infections and direct costs associated with treating those infections. The ARROW® CVC with ARROWg+ard® Technology outperformed the unprotected CVC in both infection reduction and total cost per patient. Within the study, the protected catheter achieved a zero infection rate per 1,000 catheter days. In contrast, the unprotected device was associated with a much higher CRBSI rate of 8.61/1,000 catheter days (7.4% of cases). The results were statistically significant. Additionally, the antimicrobial protected catheter was also associated with prolonged CRBSI-free time compared to the unprotected catheter, including dwell times of up to 25 days without a bloodstream infection. The study focused only on Central Venous Catheters (CVCs) inserted into the femoral area. The researchers compared infection rates and cost-effectiveness of an unprotected CVC versus a catheter protected with ARROWg+ard® Technology inserted into this infection-prone region. ARROWg+ard® Technology is an antimicrobial protection of chlorhexidine and silver sulfadiazine bonded to the catheter's surface to reduce catheter-related bloodstream infections [CRBSIs]. The research goal was to determine if the chlorhexidine/silver sulfadiazine CVC could reduce bloodstream infection rates and reduce the cost of diagnosing and treating an infection.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $112.24 USD +0.53

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hill-Rom Holdings Inc $48.61 USD -0.10
PerkinElmer Inc $44.32 USD +0.03
Sirona Dental Systems Inc $92.27 USD +0.20
STERIS Corp $67.20 USD +1.02
West Pharmaceutical Services Inc $51.15 USD +0.45
View Industry Companies
 

Industry Analysis

TFX

Industry Average

Valuation TFX Industry Range
Price/Earnings 29.6x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 26.9x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit www.teleflex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.